Sarepta raises $300M in bumped-up follow-on

Duchenne muscular dystrophy (DMD) company Sarepta Therapeutics Inc. (NASDAQ:SRPT) raised $300 million through the sale of 5 million shares at $59.75 in a follow-on underwritten by JPMorgan, Goldman Sachs, Credit Suisse, Baird, Needham, Oppenheimer, Wedbush PacGrow and WBB Securities.

After market hours Wednesday, the company proposed to raise $225 million when its stock was at $56.22. Sarepta gained $4.75 to $60.97 on Thursday, and priced the offering after market close. ...